Board of Directors
Remy Luthringer, PhD
Dr. Remy Luthringer was named Executive Chairman of the Board on February 5, 2018 and has served as the Chief Executive Officer of Minerva Neurosciences, Inc. since November 2014. He has been involved in the development of more than 150 active molecules for clinical trials in the central nervous system. Dr. Luthringer is an Advisor at Medicxi Ventures, formerly Index Ventures, a venture capital firm comprising all of the life sciences portfolio companies, funds and team from Index Ventures. Previously, he served as Chief Medical Officer for Index Ventures, with a focus on investments in healthcare infrastructure. He was also the head of the FORENAP Institute for Research in Neurosciences and Neuropsychiatry in France. Dr. Luthringer has extensive experience in clinical psychiatric practice and holds a PhD in neurosciences and clinical pharmacology.
William F. Doyle
Mr. Doyle joined the Board in December, 2017. He is Executive Chairman of Novocure Ltd. (NASDAQ: NVCR), a commercial stage oncology company, where he has served as Chairman of the Board since 2009 and a director since 2004. Mr. Doyle is also the Managing Director of WFD Ventures LLC, a private venture capital firm. Previously, he was a member of Johnson & Johnson’s Medical Devices and Diagnostics Group Operating Committee and Vice President, Licensing and Acquisitions. While at J&J, Mr. Doyle was also Chairman of the Medical Devices Research and Development Council, Worldwide President of Biosense-Webster, Inc. and a member of the boards of Cordis Corporation and Johnson & Johnson Development Corporation, J&J’s venture capital subsidiary. Earlier he was a management consultant at McKinsey & Company. Mr. Doyle holds an S.B. in materials science and engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.
Hans Peter Hasler
Hans Peter Hasler has served on our Board Since December, 2017. Mr. Hasler was the Chief Executive Officer of Vicarius Pharma AG, a privately held European Bio-Pharma company until 2020. His prior experiences include Elan Corporation, Dublin, where he was Chief Operating Officer, and Biogen Inc., Boston, where his positions included Chief Operating Officer, and EVP, Head of Global Neurology and International.
Previously, Mr. Hasler was at Wyeth Pharmaceuticals, Radnor/PA, as Senior Vice President, Chief Marketing Officer and beforehand Managing Director of Wyeth Group Germany, Münster. Mr. Hasler is Chairman of the Board of HBM Healthcare Investments AG in Switzerland (SIX), Chairman of the Board of Shield Therapeutics, London (AIM), and a Director of Gain Therapeutics (Nasdaq). He holds a Federal Swiss Commercial Diploma and a Marketing Manager Certificate from the Swiss Institute of Business Economy SIB, Zurich.
Jan van Heek
Jan van Heek has served on our Board since July 2014. Since 2009, Mr. van Heek has been a Principal and Partner at BioPoint Group, a business development consulting company, where he advises biotechnology and other healthcare companies in commercial strategy development, financing and business development. Prior to establishing BioPoint in 2009, Mr. van Heek spent more than 18 years at Genzyme Corporation, a Sanofi pharmaceutical company, most recently as an Executive Vice President and Senior Advisor to the chief executive officer and senior management team. Mr. van Heek is currently a board member of Amarin Corporation, a publicly traded biopharmaceutical company. He was also a board member and Chairman of the Audit Committee of ViaCell Corporation, a public company, from 2002 until it was sold to Perkin Elmer Corporation in 2007. He received an M.B.A. from St. Gallen University in Switzerland and an executive degree from Stanford Business School.
Jeri Hilleman joined our Board in July 2018. She has an extensive life sciences background that includes high growth commercial biopharma, med-tech and data science companies. Ms. Hilleman is Chief Financial Officer of Intersect ENT (Nasdaq: XENT), a medical device company with commercial products for the treatment of chronic sinusitis. Previously, she served as CFO of several public companies, including Amyris, Symyx Technologies (acquired), Ocera (acquired) and Cytel (acquired). Ms. Hilleman is also a member of the Board of Directors and Audit Committee of NovoCure and served previously as a member of the Board of Directors and Chair of the Audit Committee of Xenoport, Inc. (acquired), a commercial biopharma company, for over ten years, from IPO through acquisition. Ms. Hilleman holds an A.B. from Brown University and an M.B.A. from the Wharton Graduate School of Business. She is a member of the 1999 class of Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute.
David Kupfer, MD
Dr. Kupfer joined our Board in November 2015. He is an international leader in psychiatry who has authored more than 1,100 articles, books and book chapters. Dr. Kupfer chaired the American Psychiatric Association Task Force for the development of the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), which defines the criteria for the diagnosis and classification of mental disorders. Dr. Kupfer received his M.D. from Yale University in 1965. He is Distinguished Professor emeritus of Psychiatry at the University of Pittsburgh School of Medicine. As director of research at Western Psychiatric Institute and Clinic (WPIC), Dr. Kupfer helped establish WPIC as one of the nation’s preeminent university-based psychiatric research centers. He is founding president of the International Society of Bipolar Disorders and was elected to the National Academy of Medicine in 1990.
Fouzia Laghrissi-Thode, MD
Dr. Fouzia Laghrissi-Thode has served on our Board since May 2015. Dr. Laghrissi-Thode has held positions of leadership at AstraZeneca, Roche, Novartis and Sandoz in a broad range of therapeutic areas, including central nervous system, cardiovascular, metabolic disease and genito-urinary health. She is currently chief executive officer and a member of the board of directors of DalCor Pharmaceuticals. Prior to joining DalCor, Dr. Laghrissi-Thode served as U.S. Vice President for the renal-cardio therapy area at AstraZeneca, Head of the South San Francisco site, and the chief executive officer of ZS Pharma, Inc. She was formerly vice president of the cardiovascular and metabolism therapy area at AstraZeneca. Dr. Laghrissi-Thode holds an M.D. from the University of Tours School of Medicine in France, is board certified in psychiatry and was an adjunct professor of psychiatry at the University of Pittsburgh.